



17 February 2023

Shareholder Update



Myopharm™ licences to BIO-E Australia

Myopharm Limited has recently completed a licencing agreement with BIO-E Australia Pty Ltd, for the GLUCOSMOOTH® brand.

About BIO-E Australia

BIO-E is a healthcare innovation company based in Victoria, Australia with 60 staff. To date they have been highly successful in the Greater China region with online sales, local manufacturing, R&D Innovation and marketing. BIO-E source elite products backed by review and science with an explicit market need. BIO-E are renowned for their marketing abilities and marketing business plans that drive large volumes through China.

BIO-E are highly experienced formulators that work alongside nutritionists, chemists, PhD scientists and also run a number of successful subscription wellness platforms with active member participation and sales. Founder Andy Tu, started cross border e-commerce in 2013, and became Australia's Top 3 distributor for VMHS products, representing leading brands such as Swisse, Blackmores, Lifespace etc. Together with his wife Julia, they co-founded BIO- E in 2015, which became one of T Mall's "RMB100m annual sales" brands in 2020.

BIO-E Founder Andy Tu: *'We are looking forward to working with Myopharm and addressing Type 2 Diabetes and weight loss solutions in China, as there has been an explosion of cases reported across China'*.

The Licencing Agreement

The Licencing agreement is a AUD\$1.5million dollar deal over a minimum of three years including equity investment and royalty income. GLUCOSMOOTH® sales into China commence quarter 2 2023.

Myopharm continues to assess and execute upon growth opportunities associated with new product launches in Australian pharmacy, hospital channels and the overseas markets that develop and support global market access and big growth opportunities. We are preparing for a period of significant activity and growth and look forward to updating Shareholders.

Regards

For further information please contact:

Myopharm

Karinza Phoenix

Executive Chair & Chief Executive Officer

kphoenix@myopharm.com

Investor Enquiries

Investor@myopharm.com

For further information please contact:

Karinza Phoenix

Myopharm Limited

Executive Chair and CEO

M: 0498 505 321

kphoenix@myopharm.com.au

Investor Enquiries:

investor@myopharm.com

About Myopharm

Myopharm is a diabetes company, developing innovative diabetes solutions that delay disease progression and improve quality of life. At Myopharm, our research and development teams develop clinically validated medical nutritional and pharmaceutical products based on an innovative multitarget approach enabled by leading scientists from a high level of evidence.

Our goal: reduce metabolic diseases that millions of people worldwide are at risk of. We acknowledge this and that now is the time to act on prevention and extending your life. New figures released by International Diabetes Federation reveal an alarming growth in the prevalence of diabetes with 541 million adults around the world are living with diabetes. All types of diabetes is now the fastest growing chronic condition in Australia. The result of this immense pressure on the health system is more pressure than cardiovascular disease and cancer.